Bioatla Stock Analysis

Bioatla Stock Analysis Notes

About 43.0% of the company shares are held by institutions such as insurance companies. The book value of Bioatla was currently reported as 0.48. The company recorded a loss per share of 1.7. Bioatla had not issued any dividends in recent years. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. For more info on Bioatla please contact Jay Short at 858 558 0708 or go to https://www.bioatla.com.

Bioatla Investment Alerts

Bioatla Upcoming and Recent Events

Bioatla Largest EPS Surprises

View All Earnings Estimates

Bioatla Stock Institutional Investors

Note, although Bioatla's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bioatla Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 81.22 M.

Bioatla Profitablity

Management Efficiency

Bioatla has return on total asset (ROA) of (0.5047) % which means that it has lost $0.5047 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3906) %, meaning that it created substantial loss on money invested by shareholders. Bioatla's management efficiency ratios could be used to measure how well Bioatla manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -1.08. The current year's Return On Capital Employed is expected to grow to -1.35. At present, Bioatla's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 217.8 M, whereas Non Currrent Assets Other are forecasted to decline to about 158.9 K.

Technical Drivers

As of the 2nd of December, Bioatla shows the Mean Deviation of 4.44, risk adjusted performance of 0.0178, and Downside Deviation of 4.98. Bioatla technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Bioatla Price Movement Analysis

Bioatla Insider Trading Activities

Bioatla Outstanding Bonds

Bioatla Predictive Daily Indicators

Bioatla Forecast Models

Bioatla's time-series forecasting models are one of many Bioatla's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bioatla's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bioatla prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bioatla shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bioatla. By using and applying Bioatla Stock analysis, traders can create a robust methodology for identifying Bioatla entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bioatla analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bioatla analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Bioatla stock analysis indicators help investors evaluate how Bioatla stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bioatla shares will generate the highest return on investment. By understating and applying Bioatla stock analysis, traders can identify Bioatla position entry and exit signals to maximize returns.

When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.